Annual EBITDA
-$181.14 M
-$74.02 M-69.10%
December 1, 2024
Summary
- As of March 13, 2025, FDMT annual EBITDA is -$181.14 million, with the most recent change of -$74.02 million (-69.10%) on December 1, 2024.
- During the last 3 years, FDMT annual EBITDA has fallen by -$112.82 million (-165.16%).
- FDMT annual EBITDA is now -1767.00% below its all-time high of -$9.70 million, reached on December 31, 2018.
Performance
FDMT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$54.33 M
-$4.90 M-9.92%
December 1, 2024
Summary
- As of March 13, 2025, FDMT quarterly EBITDA is -$54.33 million, with the most recent change of -$4.90 million (-9.92%) on December 1, 2024.
- Over the past year, FDMT quarterly EBITDA has dropped by -$13.50 million (-33.06%).
- FDMT quarterly EBITDA is now -692.72% below its all-time high of -$6.85 million, reached on June 30, 2021.
Performance
FDMT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$181.14 M
-$19.19 M-11.85%
December 1, 2024
Summary
- As of March 13, 2025, FDMT TTM EBITDA is -$181.14 million, with the most recent change of -$19.19 million (-11.85%) on December 1, 2024.
- Over the past year, FDMT TTM EBITDA has dropped by -$56.05 million (-44.80%).
- FDMT TTM EBITDA is now -1460.71% below its all-time high of -$11.61 million, reached on September 30, 2019.
Performance
FDMT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FDMT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -69.1% | -33.1% | -44.8% |
| 3 y3 years | -165.2% | -332.0% | -82.4% |
| 5 y5 years | -305.9% | -332.0% | -82.4% |
FDMT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -165.2% | at low | -332.0% | at low | -165.2% | at low |
| 5 y | 5-year | -305.9% | at low | -692.7% | at low | -556.9% | at low |
| alltime | all time | -1767.0% | at low | -692.7% | at low | -1460.7% | at low |
4D Molecular Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$181.14 M(+69.1%) | -$54.33 M(+9.9%) | -$181.14 M(+11.9%) |
| Sep 2024 | - | -$49.43 M(+21.1%) | -$161.94 M(+29.5%) |
| Jun 2024 | - | -$40.83 M(+11.7%) | -$125.09 M(+8.8%) |
| Mar 2024 | - | -$36.54 M(+4.0%) | -$114.97 M(+7.3%) |
| Dec 2023 | -$107.12 M(+0.9%) | -$35.14 M(+179.4%) | -$107.12 M(+7.9%) |
| Sep 2023 | - | -$12.58 M(-59.0%) | -$99.31 M(-11.6%) |
| Jun 2023 | - | -$30.71 M(+7.0%) | -$112.35 M(+2.8%) |
| Mar 2023 | - | -$28.69 M(+5.0%) | -$109.24 M(+2.9%) |
| Dec 2022 | -$106.15 M(+55.4%) | -$27.33 M(+6.7%) | -$106.15 M(+3.2%) |
| Sep 2022 | - | -$25.62 M(-7.2%) | -$102.81 M(+3.7%) |
| Jun 2022 | - | -$27.59 M(+7.8%) | -$99.10 M(+26.5%) |
| Mar 2022 | - | -$25.61 M(+6.7%) | -$78.36 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$68.31 M(+23.7%) | -$23.99 M(+9.6%) | -$68.31 M(+6.1%) |
| Sep 2021 | - | -$21.90 M(+219.5%) | -$64.37 M(+29.0%) |
| Jun 2021 | - | -$6.85 M(-56.0%) | -$49.92 M(-13.7%) |
| Mar 2021 | - | -$15.56 M(-22.4%) | -$57.85 M(+4.8%) |
| Dec 2020 | -$55.22 M(+23.8%) | -$20.05 M(+169.2%) | -$55.22 M(+8.0%) |
| Sep 2020 | - | -$7.45 M(-49.6%) | -$51.14 M(-7.5%) |
| Jun 2020 | - | -$14.79 M(+14.4%) | -$55.30 M(+36.5%) |
| Mar 2020 | - | -$12.93 M(-19.0%) | -$40.51 M(+46.9%) |
| Dec 2019 | -$44.62 M(+359.9%) | -$15.97 M(+37.6%) | -$27.58 M(+137.6%) |
| Sep 2019 | - | -$11.61 M | -$11.61 M |
| Dec 2018 | -$9.70 M(-8.9%) | - | - |
| Dec 2017 | -$10.65 M | - | - |
FAQ
- What is 4D Molecular Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for 4D Molecular Therapeutics?
- What is 4D Molecular Therapeutics annual EBITDA year-on-year change?
- What is 4D Molecular Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for 4D Molecular Therapeutics?
- What is 4D Molecular Therapeutics quarterly EBITDA year-on-year change?
- What is 4D Molecular Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for 4D Molecular Therapeutics?
- What is 4D Molecular Therapeutics TTM EBITDA year-on-year change?
What is 4D Molecular Therapeutics annual EBITDA?
The current annual EBITDA of FDMT is -$181.14 M
What is the all time high annual EBITDA for 4D Molecular Therapeutics?
4D Molecular Therapeutics all-time high annual EBITDA is -$9.70 M
What is 4D Molecular Therapeutics annual EBITDA year-on-year change?
Over the past year, FDMT annual EBITDA has changed by -$74.02 M (-69.10%)
What is 4D Molecular Therapeutics quarterly EBITDA?
The current quarterly EBITDA of FDMT is -$54.33 M
What is the all time high quarterly EBITDA for 4D Molecular Therapeutics?
4D Molecular Therapeutics all-time high quarterly EBITDA is -$6.85 M
What is 4D Molecular Therapeutics quarterly EBITDA year-on-year change?
Over the past year, FDMT quarterly EBITDA has changed by -$13.50 M (-33.06%)
What is 4D Molecular Therapeutics TTM EBITDA?
The current TTM EBITDA of FDMT is -$181.14 M
What is the all time high TTM EBITDA for 4D Molecular Therapeutics?
4D Molecular Therapeutics all-time high TTM EBITDA is -$11.61 M
What is 4D Molecular Therapeutics TTM EBITDA year-on-year change?
Over the past year, FDMT TTM EBITDA has changed by -$56.05 M (-44.80%)